Open access peer-reviewed chapter

Dental Implants in the Medically Compromised Patient Population

Written By

Ayşe Sümeyye Akay and Volkan Arısan

Submitted: 21 November 2016 Reviewed: 21 June 2017 Published: 20 December 2017

DOI: 10.5772/intechopen.70182

From the Edited Volume

Clinical Trials in Vulnerable Populations

Edited by Milica Prostran

Chapter metrics overview

1,441 Chapter Downloads

View Full Metrics

Abstract

As a result of the increase of the life expectancy, elder people live with diverse diseases or conditions like systemic disorders, immune-related disorders, and psychiatric issues. Consecutively, practicing clinicians are faced with serving dental implant treatments in such a population comprised of medical and demographic characteristics. Most commonly, implant therapy is performed among patients above middle ages; therefore, clinicians often encounter medically compromised patients. The patients are usually with adverse conditions like bleeding disorders, bone diseases, cardiovascular disease (CVD), and/or immunologic conditions like cancer therapy, steroid or immunosuppressive or antiresorptive medication, alcoholism, smoking, and many others. Nevertheless, only few conditions could be stated for contraindication to dental implant therapy. Besides the broad range of the mentioned dental implant comorbidities smoking seems less prevalent compared to the general population. Dental implants in smoking patients are certainly affected in relation to the failure rate, marginal bone loss, and some other risks of postoperative complications. Hence, smoking or other similar conditions could be accounted as a chronic systemic disorder just like diabetes mellitus or drug usage. Briefly, it seems that establishing the medical and demographic conditions prior to implant therapy along with controlling the systemic diseases or disorders may be more important than the presence of compromise.

Keywords

  • systemic diseases
  • dental implant success
  • contraindication

1. Introduction

Dental implant (DI) is broadly considered to be the ideal treatment of the tooth loss, which is mostly required in the aged population [1, 2]. The prevalent age-range for implant therapy has been reported above 40 years [2] or between 51 and 60 years [1], thus the patients who required dental implant therapy are usually associated with systemic comorbidities. For both patients’ and clinicians’ benefit, systemic comorbidities of the patient should be well-diagnosed before DI therapy. Besides, treatment plan and patient selection should be carried out with reference to the clinical evidence. Patients should be ensured to inform thoroughly about the risks and precautions.

Advertisement

2. Systemic disorders and compromised conditions

2.1. Elderly population

Aging has an effect on biological activity via altering the inflammatory, regenerative, and remodeling phases of healing process. First, it makes inflammatory phase prolonged by promoting the release of inflammatory mediators. Second, it decreases new tissue formation in the regenerative phase by reducing angiogenesis and the number of mesenchymal stem cells, which are the progenitors of new bone formation. Last, it causes an imbalance in bone remodeling by changing cell activity, level of matrix metalloproteases, apoptosis, and collagen turnover [3]. Therefore, it may not be wrong to consider that aging causes a delay on osseointegration of dental implants.

In the literature, there are eligible studies that have been conducted for long-term time periods and the survival rate (SR) of dental implants is about 90% ( Table 1 ). Furthermore, in a recent meta-analysis, SR has been reported to be 91.2% for up to 10 years [4]. On the other hand, considering the peri-implant pathology and bone level changes, studies have unsatisfactory results. According to the aforementioned meta-analysis [4], there is only one prospective clinical study that reports peri-implant marginal bone loss (MBL) after 10 years as 1.5 mm [5]. Additionally, another reviewer states that peri-implant mucositis and peri-implantitis are observed more commonly in totally edentulous patients, which are mainly ≥65 years old [3].

Author, year, study design Follow-up No. of patients No. of implants SR of implant Peri-implant pathology Conclusion
Moy et al., 2005, Retrospective cohort [6] 2–20 years 541 subjects are aged >60 years (1140 total) ND (4680 total) 82% (for aged >60 years) Patients who are aged >60 years have higher risk for implant failure (RR = 2.24)
Manor et al., 2009, Retrospective cohort [7] 6 years 194 (2 equal groups for evaluating early and late failures) 294 Assigned as minor/moderate/major MBL Old age may be a risk factor for late failures and risk is also more likely for men and posterior of jaws
Lee et al., 2010, Prospective [8] 2.7 years (mean) 35 subjects are >70 aged geriatric MCP with controlled systemic disease 118 MBL: 0.27 mm Old age is not a risk factor for peri-implant MBL (p = 0.484)
Busenlechner et al., 2014, Retrospective [9] 8 years 2632 subjects are >50 years (61% out of 4316 total) ND 95.3% for the age >70 years Old age over 70 years is not associated with long-term implant success
Becker et al., 2015, Prospective [10] 7 years 31 aged subjects 84 94.6% for 13 patients with 40 implants MBL: 0.1 mm (difference of 0–7 years’ follow-up)
PD: 2.6 mm
DI is successful in aged population, and MBL changes are comparable with the younger populations
Neves et al., 2016, Retrospective [2] 7.3 years (mean) 528 subjects are aged >40 years (721 total MCP subjects with the age range of 20–87) ND (3998 total) 92.7% for the age <40, 85.3% for age >40, and 86.5% is overall SR (patient based) 33.8% of patients and 12.7% of implants have pathology >40 age is a risk factor of implant loss (risk is higher for more than two times than <40 age), but is not a risk for peri-implant pathology
Prasad et al., 2016, Retrospective cohort [11] 5.7 years of mean Approximately the half of 1091 total subjects is aged >60 years ND (1918 total) 96.4% (implant based), 94.6% (patient based) Age over 65 years is shown to have an increased risk of implant failure
Hoeksema et al., 2016, Prospective comparative [5] 10 years (1) 52 subjects with age range of 35–50 years
(2) 53 subjects with age range of 60–80 years
(1) 104
(2) 106
(1) 97.1%
(2) 93.4%
MBL: 0.1 mm (1st year), 0.7 mm (5th year), 1.5 mm (10th year)
PD: 3 mm for both groups at 10th year
Mandibular two-implant OD is equally successful in older patients compared with the younger patients without significant differences of the parameters
Srinivasan et al., 2016, Sys. Rev., meta-analysis [4] (includes 11 prospective studies) 1–10 years 206 subjects are aged ≥65 years 480 97.7% (1st year), 96.2% (5th year), 91.2% (10th year) MBL: 0.1–0.3 mm (1st year), 0.7 mm (5th year), 1.5 mm (10th year) Age alone should not be a limiting factor for DI therapy Reported complications are found inadequate for a meta-analysis
Mean/total of values/subjects and considerations 1–20 years 4765 patients above middle ages >1082 SR is 90% for long-term period 0.1 mm in the 1st, 1.7 mm in the 5th, and 1.5 mm in the 10th year follow-ups (out of 3 in available 8 studies) Implant therapy is a successful treatment in the medically compromised patient

Table 1.

Studies that indicate dental implant outcomes in the elderly population.

MCP, medically compromised patients; DI, dental implant; SR, survival rate; MBL, marginal bone loss; BoP, bleeding on probing; RR, risk ratio; ND, no data available; OD, overdenture.

2.2. Tobacco smoking

Tobacco consumption is one of the main considerable patient-related systemic conditions for the patients who require DI. Though smoking is not a contraindication for DI therapy, there have been a lot of studies that report negative effects on DI outcomes.

According to the clinical studies ( Table 2 ), there is a tendency to consider that implant failure is correlated with smoking habits. Most of the studies confirm the association between smoking and increased failure rate of implants in both short- and long-term periods. Besides, tobacco smoking has been proved to increase the failure rate of DI from 2.5- to 3-fold [9, 12]. However, there is only one study that has showed a higher survival rate of DI in smoker patients [13].

Author, year, study design Follow-up No. of patients No. of implants SR of implant Peri-implant pathology Conclusion
Ekfeldt et al., 2001, Retrospective controlled study [17] (half of subjects lost at least half of their implants) 8 years 54 total (half part is smoker, and 9 of them defined as heavy smokers who consumed ≥10 cig/day) ND 31 DI loss in 7 heavy smokers (at least half of their implants) 6% of implants had infection during healing in smokers Except from instability associated with bad bone quality, implant losses mostly occur in patients with heavy smoking habits or bruxism. It is more prominent in post-loading period (22 implants had lost after loading in 7 patients of heavy smokers)
Moy et al., 2005, Retrospective [6] 2–20 years 173 smoker ND 79.77% for smokers There is a correlation between smoking and increased failure rate (RR = 1.56)
Galindo-Moreno et al., 2005, Prospective [15] 3 years 63 smoker ND (514 total) MBL is 1.36 mm in smokers MBL is significantly related to tobacco smoking
Alsaadi et al., 2007, Retrospective [18] Up to the abutment connection ND (2004 total) 6946 total (343 heavy smoker who consumed >20 cig/day) 92.95% for heavy smokers Smoking of >20 cig/day is shown significantly higher early implant failure when compared to no smoking groups
Holahan et al., 2008, Retrospective chart review [19] 5 years 24 smoker 83 in smokers 88% for smokers Implants placed in smokers are 2.6 times more likely to fail than implants placed in nonsmokers
Sverzut et al., 2008, Retrospective [20] <1 year 76 smoker (out of 650 total) 197 in smokers (1628 total) 97.19% for smokers, 96.68% for nonsmokers Tobacco use alone cannot be considered as a factor for risk related to early implant failures
Alsaadi et al., 2008, Retrospective [21] 2 years 22 (>20 cig/day) 93 implants in patients who consumed >20 cig/day 93.94% Smoking does not seem predominant player for late implant loss
Alsaadi et al., 2008, Prospective [22] <1 year 90 smoker 95 in smokers 94.44% Tendency for more early implant failures is noticed in smokers
Lee et al., 2011, Retrospective [23] 5 years ND (95 total) ND (249 total) ND ND Implant failures are correlated with smoking
Cakarer et al., 2014, Retrospective [24] 5 years ND 246 in smokers 97.5% (6 failed out of 246 implant) Smoking is not affected the DI survival
Busenlechner et al., 2014, Retrospective [9] 8 years 1726 smoker ND (13147 total) 76.5% for smokers (overall SR is 97%) Smoking increases the failure rate by 3-fold 6–15 cig/day doubles the risk of implant failure
Tran et al., 2016, Retrospective chart review [12] 10 years 215 smoker (2729 total) Smoking increases the failure rate by 2.6-fold
Krennmair et al., 2016, Prospective cohort [16] 3 years 9 smoker (out of 44 total) ND 1.45 * mm in smokers Smoking is risk factors for MBL (OR: 8.9)
Neves et al., 2016, Retrospective [2] 7.3 years of mean 476 smoker ND 85.1% (patient based) 36.6% pathology rate (patient based) Smoking is not associated with higher risk of implant failure and peri-implant pathology (>4 mm pocket depth with BoP or MBL)
Pedro et al., 2017, Analytical, observational, longitudinal study [25] 2–4 years ND (18 total) ND (57 total) ND Smoking has an influence on both mesial and distal bone loss (p = 0.037)
Niedermaier et al., 2017, Retrospective cohort [13] 7 years 141 smoker (out of 380 total) ND (2081 total) 98.6% for smokers, 96.1% for nonsmokers Smokers have a significantly higher DI survival rate than nonsmokers
Clementini et al., 2014, Systematic review and meta-analysis [14] >1 year 478 smoker and 1207 nonsmoker ND ND Smoking increases the annual rate of MBL by 0.164 mm/year Smoking has a harmful effect on peri-implant bone loss. However, the level of evidence for oral implant therapy in patients with systemic conditions is very low
Mean/total of values/subjects 1–20 years 3520 patients with smoking habits (13 out of 17 available studies) 1057 implants in smokers (6 out of 17 available studies) SR is about 90% for smokers Apprx. 1.4 mm MBL after 3 years Smoking has a negative impact on the success and survival of dental implants

Table 2.

Studies that indicate dental implant outcomes in patients with smoking habits.

Statistically significant difference with healthy groups.


DI, dental implant; SR, survival rate; MBL, marginal bone loss; BoP, bleeding on probing; OR, odds ratio; RR, risk ratio; ND, no data available.

People who consume 10–20 cigarettes daily are often counted as heavy smokers in clinical studies. And despite a small number of studies that reveal the effect of the number of cigarettes on failure, it has been demonstrated that consuming the 6–15 cig/day doubled the risk of implant failure [9].

Regarding the MBL, smoking seems to have a destroying effect by increasing the annual rate of MBL by 0.164 mm/year [14], and MBL is about 1.4 mm after 3 years with a statistically significant difference from people who do not smoke tobacco [15, 16].

As a result, tobacco smoking alone is not contraindicated for DI, and DI survival is about 90% for a long time period. On the other hand, smokers are under a higher risk of implant failure compared to the nonsmokers. Thus, clinicians should take into account other concomitant systemic factors which could increase the risk of failures.

2.3. Alcohol consumption

There is no evidence to suggest that alcoholism is a contraindication for DIs. SR of DI is similar to healthy population with a reasonable alcohol consumption. Nevertheless, alcoholism is claimed to increase the risk of complications for DI because it may cause many systemic disorders like liver disease, bleeding disorders and osteoporosis (OP), and it may impair immune response and some nutritional elements like folate and B vitamins, and it is often associated with tobacco smoking [28].

It is reported that consumption of >10 g of alcohol increases the MBL and decreases DI survival in humans [15]. Despite there are few studies available ( Table 3 ) concerning the DI outcomes in patients who consumed high level of alcohol, further clinical studies with well-defined subjects are required for clarifying the relation.

Author, year, study design Follow-up No. of patients No. of implants SR of implant Peri-implant pathology Conclusion
Galindo-Moreno et al., 2005, Prospective [15] 3 years 23 alcohol users ND MBL: 1.66 mm MBL is significantly related to a daily consumption of >10 g of alcohol
Gander et al., 2014, Retrospective [26] 20 months 33 (29 patients with SCC, 24 underwent mandibular reconstruction) 136 total 92.7% (at 1st year), 87.5% (after 20th month) In head and neck oncology patients alcohol (p = 0.001) is associated with higher implant failure rate
Scully et al., 2007, Review [27] ND ND ND Similar to healthy population May not be a risk for DI
Diz et al., 2013, Review [28] ND ND ND Similar to healthy population May be at increased risk of complications for DI

Table 3.

Studies that indicate dental implant outcomes in patients with alcohol abuse.

MBL, marginal bone loss; ND, no data available; SR, survival rate; SCC, squamous cell carcinoma; DI, dental implant.

2.4. Cardiovascular diseases

Cardiovascular disease (CVD) compromises the blood flow which may restrict oxygen or nutrients in the osseous tissue, thus is hypothesized to have higher risk of osseointegration failure [29, 30, 31]. Clinical studies and reviews demonstrate no evidence of contraindication related to DI success in patients with CVD ( Table 4 ), and this disease is registered as a relative complication due to the risk of infective endocarditis. Antibiotic prophylaxis is necessary prior to the surgery [31] according to the guidelines of the American Heart Association’s last publish [32, 33].

Author, year, study design Follow-up No. of patients No. of implants SR of implant Peri-implant pathology Conclusion
Moy et al., 2005, Retrospective cohort [6] 2–20 years 1140 total (202 with hypertension, 106 with CVD, 75 with pulmonary disease) ND (4680 total) 85% for hypertension, 85% for CVD There is no correlation between hypertension, coronary artery disease, pulmonary disease and increased failure rate of DI
Alsaadi et al., 2007, Retrospective [18] Up to the abutment connection ND (2004 total) ND (6946 total) ND Cardiac disease is not associated with increased incidence of the early failures
Alsaadi et al., 2008, Retrospective [21] 2 years 19 subjects with CVD 76 in subjects with CVD 90.79% Cardiac problem does not seem a predominant player for late implant loss
Neves et al., 2016, Retrospective [2] 7.3 years of mean 222 subjects with CVD ND 89.2% (patient based) 32% (patient based) Cardiac disease is not associated with higher risk of implant failure and peri-implant pathology (>4 mm pocket depth with BoP or MBL)
Nobre et al., 2016, Retrospective [38] 5 years after loading 70 total (CVD subjects: 38 patients; non-CVD subjects: 32 patients) 352 CVD: 86.7%; non-CVD: 93.8% MBL at 1st and 5th year is 0.95–1.52 mm in CVD; 0.78–1.54 mm in non-CVD group Implant rehabilitations represent a valid treatment for diabetic patients with or without coexisting CVD, with a good risk/benefit ratio (nonsignificant differences between the groups)
Krennmair et al., 2016, Prospective cohort [16] 3 years 19 subjects with CVD (out of 44 total) ND 1.38 mm in CVD * CVD is risk factors for bone loss. (OR: 5.1)
Pedro et al., 2017, Analytical, observational, longitudinal [25] 2–4 years ND (18 total) ND (57 total) ND Heart diseases are not a contraindication for DI bone loss
Niedermaier et al., 2017, Retrospective cohort [13] 7 years 95 subjects with CVD (380 total) ND (2081 total) 97.8% DI survival in patients with cardiovascular problems does not differ from the healthy control subjects
Mean/total of values/subjects 2–20 years 1533 patients with CVD (in 6 out of 8 available studies) 428 (in 2 out of 8 available studies) Approx. 89% SR 0.95 mm at 1st year
1.38 mm at 3rd year
1.52 mm at 5th year
CVD may not pose a risk for dental implants

Table 4.

Studies that indicate dental implant outcomes in patients with cardiovascular diseases.

Statistically significant difference with healthy groups.


CVD, cardiovascular disease; RD, rheumatic disorders; OR, odds ratio; MBL, marginal bone loss; ND, no data available; SR, survival rate.

DI surgery is suggested as a legitimate procedure for the patients at high risk for IE (such as aortic or mitral valve replacement or cyanotic congenital malformation) which under prophylactic antibiotic regime of 2 g amoxicillin orally at 1 hour preoperatively [34]. There is also evidence suggesting that this regimen significantly reduces failures of DIs though it is still unknown whether postoperative antibiotics are more beneficial, and which antibiotic is the most effective [33]. Reviewers stated the importance of concomitant bleeding or cardiac ischemia which could develop during DI insertion, therefore, procuring medical advice is recommended prior to the implant surgery [28]. As a matter of fact, recent myocardial infarction, stroke, and cardiovascular surgery are well-known contraindications for performing DI surgery [35].

According to the current literature, CVD does not hinder the osseointegration of DI [36, 37] and is not associated with higher risk of implant failure ( Table 4 ). SR is about 89% up to 20 years ( Table 4 ). However, the number of the studies that reports peri-implant health condition is insufficient. Unlike the other studies available, one study revealed that CVD has risk factors for peri-implant bone loss with the mean value of 1.38 mm after 3 years [16]. Further studies are needed in this respect.

2.5. Diabetes

As being the most prevalent endocrine disease, diabetes mellitus is a metabolic disorder that is generally diagnosed by the characteristic symptoms of polydipsia, polyuria, and polyphagia in correlation with exceeded blood glucose levels more than 200 mg/dL. It causes hyperglycemia due to a defect of insulin secretion [39], that insulin has an effect on the regeneration of bone matrix. In a diabetic patient, hyperglycemia reduces clot quality, number of osteoclasts, and collagen production, which are the keys of bone regeneration [30].

A decreased bone density is observed around the titanium implants in animal subjects, and implant survival is slightly reduced in poor metabolic control [28] with an average rate of 89% ( Table 5 ). Yet no clinical evidence exists to establish an association of glycemic control with implant failure because of the insufficient identification and reporting of glycemic control in most of the published studies [40].

Author, year, study design Follow-up No. of patients No. of implants SR of implant Peri-implant pathology Conclusion
Moy et al., 2005, Retrospective cohort [6] 2–20 years 48 diabetic ND 68.75% in diabetic patients There is a correlation between diabetes and increased failure rate (RR = 2.75)
Alsaadi et al., 2007, Retrospective [18] Up to the abutment connection ND ND ND Controlled diabetes type 2 is not associated with increased incidence of the early failures
Alsaadi et al., 2008, Retrospective [21] 2 years 9 33 100% Diabetes type 2 does not seem predominant player for late implant loss
Busenlechner et al., 2014, Retrospective [9] 8 years 185 (4.3% out of 4316 total) ND 95.1% for diabetes (overall 97%) Diabetes is not associated with long-term implant survival (p = 0.928)
Neves et al., 2016, Retrospective [2] 7.3 years (mean) 56 diabetic ND 92.9% (patient based SR) 26.8% patient based Diabetes is not associated with higher risk of implant failure and peri-implant pathology (>4 mm PD with BoP/MBL)
Niedermaier et al., 2017, Retrospective cohort [13] 7 years 9 ND 91.9% DI survival in diabetic patients does not differ from the healthy control subjects
Shi et al., 2016 Meta-analysis [41] (abstract available) ND 252 587 ND There is no difference between the failure rates of the patients with uncontrolled and well-controlled diabetes
Diz et al., 2013, Review [28] ND ND ND Slightly reduced in bad metabolic control Evaluating the HbA1c level for patient selection, avoiding hypoglycemia, using chlorhexidine and antibiotic prophylaxis are recommended for diabetic patients
Oates et al., 2013, Review [40] Unrestricted Implant failure rates ranging from 0 to 9.1% Clinical evidence is lacking for the association of glycemic control with implant failure, because the identification and reporting of glycemic control are insufficient or lacking in most of the published studies
Mean/total of values/subjects 2–20 years 559 diabetic patients (in 6 out of 7 available studies) 620 (in 2 out of 7) Approx. 89% SR Diabetes may interfere with the SC and SR pf implants

Table 5.

Studies that indicate dental implant outcomes in patients with diabetes.

DI, dental implant; BoP, bleeding on probing; MBL, marginal bone loss; ND, no data available; SR, survival rate; RR, risk ratio; PD, pocket depth.

Though diabetes is not a contraindication for DI therapy, evaluating the HbA1c level of the patient and chlorhexidine mouth wash and antibiotic prophylaxis are recommended in order to reduce the relative risk of infection associated with diabetes [28, 30].

2.6. Bleeding disorders

There is no evidence to suggest that bleeding disorders (BDs) are contraindication for placement of DIs [28] or a contraindication for implant survival/success [31]. Since the risk of thromboembolism of interrupting or changing the antiplatelet therapy is higher than the risk of hemorrhage caused by dental implant surgery, invasive dental procedures including dental implant surgery are suggested to perform normally [42].

Considering the oral anticoagulant therapy (OAT), DI is not contraindicated in patients under an OAT [28, 31]. Minor DI surgery (that does not involve autogenous bone grafts, extensive flaps, or osteotomy preparations extending outside the bony envelope) is asserted to be safe regarding the risk of hemorrhage in patients who have an INR value of 2–4, and local hemostatic agents are suggested enough for these patients [43, 44]. On the other hand, it should be noted that some medications that are commonly used in dental practice (like metronidazole, erythromycin, and clarithromycin) may increase the anticoagulant effect of warfarin [31].

There are some additional precautions for the patients with inherited BDs such as taking medical advice previously, the replacement of deficient coagulation factor to reach a minimum level of 50% before surgery, slow injection of local anesthesia with vasoconstrictor, the use of antifibrinolytic agents (oral tranexamic acid and/or 5% tranexamic mouthwash) up to 7 days postsurgically, and the use of topical antiseptics (chlorhexidine or povidone iodine) in order to reduce the risk of local infection. Sinus lifting and bone graft procedures are recommended to be avoided, and consulting for the use of nonsteroidal anti-inflammatory drugs is advised as they may increase the risk of a dangerous hemorrhage [31].

Studies that analyze the bleeding risk and DI success after invasive DI surgeries are lacking ( Tables 6 and 7 ). Studies are also required for evaluating whether anticoagulants have an effect on DI therapy negatively or which is the optimum drug or regimen.

Author, year, study design Objective of the study No of patients Conclusion related to surgical risks of DI
Clemm, 2016, Clinical comparative study [45] Postoperative bleeding risk of patients continuing their anticoagulation therapy (antiaggregant, vit-K inhibitors, vitamin-K inhibitor withdrawal bridged with heparin, direct oral anticoagulants) and undergoing implant surgery and advanced bone grafting procedures 564 patients
  1. No thromboembolic complication occurred

  2. The postoperative bleeding risk after implant surgery and/or bone grafting procedures is very low in patients continuing the anticoagulant therapy

  3. The invasiveness of the surgical procedure had no statistically significant effect on bleeding frequencies

  4. Patients taking vit-K inhibitors had a significantly higher risk of a postoperative bleeding compared to patients without any anticoagulant

  5. Most of the postoperative bleedings are easily controllable via local hemostatic measures

Table 6.

Hemorrhagic risks in patients undergoing advanced implant surgery and bone grafting procedures.

Author, year, study design Follow-up No. of patients No. of implants SR of implant Peri-implant pathology Conclusion
Markovic et al., 2016, Randomized study [46] 1 year 20 80 100% for both groups There is no difference between healing of the hydrophilic and hydrophobic TiZr implant surface. OAT influences the bone healing by resulting in lower ISQ at 3rd month in comparison with baseline values, although without compromising implant stability

Table 7.

Studies that indicate dental implant outcome in patients with bleeding disorders or under an anticoagulant therapy.

OAT, oral anticoagulation therapy; ISQ, implant stability quotient; SR, survival rate.

2.7. Thyroid disorders

Thyroid hormones of triiodothyronine (T3) and thyroxine (T4) have been demonstrated to have influence on cortical bone healing than cancellous bone around titanium implants [47]. Thus, thyroid hormones-related disorders could be regarded as the considerable issues for evaluating the success of dental implants.

Concerning the peri-implant pathology, thyroid disorders are reported to have the lowest potential risk compared to the other systemic disorders, in a recent clinical study [2] ( Table 8 ). Due to the limited number of clinical studies that report DI outcomes in patients with thyroid disorders, it is hard to deduce a suggestion. Therefore, there is a certain need for further studies about the thyroid disorders.

Author, year, study design Follow-up No. of patients No. of implants SR of implant Peri-implant pathology Conclusion
Alsaadi et al., 2008, Retrospective [21] 2 years 25 Hypo-
6 Hyper-
111 Hypo-
22 Hyper-
93.69% Hypo-
86.36% Hyper-
Hypo- or hyperthyroidism does not seem a predominant player for late implant loss
Neves et al., 2016, Retrospective [2] 7.3 years of mean 37 ND 86.5% (patient based SR) 18.9% (patient based) Thyroid disorders are associated with neither higher risk of implant failure nor peri-implant pathology (>4 mm PD with BoP or MBL)
Mean/total of values/subjects Up to 7 years 68 133 (in one study available) Further studies are required

Table 8.

Studies that indicate dental implant outcomes in patients with thyroid disorders.

BoP, bleeding on probing; MBL, marginal bone loss; ND, no data available; SR, survival rate; PD, pocket depth.

2.8. Hepatitis

Concerning the dental implantology, hepatitis is one other disease which has not been studied widely yet. These infectious diseases impair immune system, increase oxidative stresses induced by the viral proteins, and cause virus-associated organ damage including liver fibrosis, steatosis, or hepatocellular carcinoma [48].

Being one of the most spread and dangerous human pathogens, hepatitis C is shown to affect the oral conditions by increasing decays, gingival bleeding, and pocket depth due to the evident change in salivary flow [49].

Though hepatitis was indicated only as a possible risk factor previously [50], a present report is registered that hepatitis is the only risk factor for peri-implant pathology among the other systemic compromising factors such as cardiac diseases, thyroid disorders, diabetes, rheumatologic disorders, HIV infection, and smoking [2] ( Table 9 ).

Author, year, study design Follow-up No. of patients No. of implants SR of implant Peri-implant pathology Conclusion
Neves et al., 2016, Retrospective [2] 7.3 years of mean 12 with hepatitis ND 83.3% (patient based) 66.7% (patient based) Hepatitis is not associated with higher risk of implant failure but it is a risk factor for peri-implant pathology (OR = 3.74) (>4 mm PD with BoP or MBL)

Table 9.

Studies that indicate dental implant outcomes in patients with hepatitis.

OR, odds ratio; BoP, bleeding on probing; MBL, marginal bone loss; ND, no data available; PD, pocket depth.

2.9. Bone diseases

Being the most frequent bone disorder, osteoporosis (OP) affects both bone mass and density. The effect is also more prominent in cancellous bone and in women [30].

Clinical studies have demonstrated that a SR of DIs in the patients with the diagnosis of OP is about 94% ( Table 10 ). Despite a small number of studies that report peri-implant conditions, one study has presented a high rate of peri-implantitis in patients with OP (76.1%), but this rate does not differ from the healthy population or the patients with osteopenia [51]. Regarding the peri-implant MBL, one recent study has reported a mean value of 0.11 mm at first year [52], and one other has reported a mean of 0.65 mm at fifth year [53]. Additionally, bone status does not seem to be a predisposition for DI failures.

Author, year, study design Follow-up No. of patients No. of implants SR of implant Peri-implant pathology Conclusion
Alsaadi et al., 2007, Retrospective [18] Up to the abutment connection ND ND ND OP is found significantly associated with early implant failures (OR: 2.88)
Alsaadi et al., 2008, Retrospective [21] 2 years 19 subjects with OP 68 86.76% OP does not seem predominant player for late implant loss
Holahan et al., 2008, Retrospective chart review [19] 5 years 41 with OP (21.4% of 192 total), 57 with OPN (29.7% of total) ND ND OP or OPN is not a contraindication to DI. No association between BMD T-score and DI survival is found
Busenlechner et al., 2014, Retrospective [9] 8 years 151 subjects with OP (3.5% out of 4316 total) ND 94.4% for OP-subjects (overall rate is 97%) OP is not associated with long-term implant survival (p = 0.661)
Dvorak et al., 2011, Cross-sectional study [51] 6 years 47 subjects with OP, 16 with OPN, 140 are healthy controls ND 81% for OPN, 87% for OP, 87% for the control Peri-implantitis rates: 75% in the OPN, 76.1% in OP group, 76.5% in the control There is no relation between (neither OPN nor OP) bone status and peri-implantitis or implant loss
Siebert et al., 2015, Comparative prospective [54] 1 year 24 women (the half was under iv. 5 mg zoledronic acid once-yearly, others without OP) 120 100% ND The mean MBL is similar for both groups. Immediate implant osseointegration can be successful in patients who received iv. zoledronic acid
Chow et al., 2016, Prospective [53] 5 year 79 subjects with OP 158 98.7% MBL 0.65 mm
BOP 49.6%
PI 47.4%
OP is not a contraindication for DI, and reduced skeletal BMD is not associated with increased MBL. BOP is found significantly correlated with MBL
Niedermaier et al., 2017, Retrospective [13] 7 years 7 subjects ND 94.1% OP under the medication with BF seems to be a risk factor for success of DI
Temmerman et al., 2017, Prospective nonrandomized controlled multicenter [52] 1 year 20 subjects with OP, 28 control subjects 63 in OP-patients, 85 in control 98.4% is for OP group,
100.0% is for control group
MBL: 0.11 ± 0.49 mm for OP group; 0.05 ± 0.52 mm for control group (implant based) DI in patients suffering from OP/OPN is a reliable treatment compared to healthy patients. Long-term follow-up is necessary
Mean/total of values/subjects 1–8 years 388 (in 8 out of 9 available studies) 409 (in 4 out of 9 available studies) 94% SR in patients with OP Mean MBLs are 0.11 mm at 1st year and 0.65 mm at 5th year follow-ups Bone disease does not seem to be associated with the peri-implantitis or failure of DIs

Table 10.

Studies that indicate dental implant outcomes in patients with bone diseases.

OP, osteoporosis; OPN, osteopenia; OR, odds ratio; ND, no data available; BMD, bone mineral density; MBL, marginal bone loss; DI, dental implant; SR, survival rate.

2.10. Rheumatologic disorders

Rheumatologic disorders encompass a large number of diseases and syndromes such as rheumatoid arthritis, osteoarthritis, and osteoporosis, which are the most common rheumatologic diseases (RDs) [2]. Different RDs could affect DI success in different ways [28]. For instance, rheumatoid arthritis (RA) has not stated a predominant player for late implant loss in one study [21]. However, together with the connective tissue disease, RA increases bone resorption when compared to the connective tissue disease alone [55].

Today, there are only a few number of clinical studies with limited amount of participants that evaluate the success of DIs in patients with RD. Although RD was shown as risk factor for peri-implant MBL in a recent prospective study [16], no relationship was found with the implant failure risk or peri-implant pathology in another study [2]. Therefore it can be concluded that any relation of RD in DI success is unclear, and there is a certain need for further studies with sufficient number of participants ( Table 11 ).

Author, year, study design Follow-up No. of patients No. of implants SR of implant Peri-implant pathology Conclusion
Alsaadi et al., 2008, Retrospective [21] 2 years 6 patients with RD 28 100% RA does not seem predominant player for late implant loss
Krennmair et al., 2016, Prospective [16] 3 years 6 patients with RD (44 total) ND 1.61 mm in RD RD is risk factors for bone loss (OR: 50.1)
Neves et al., 2016, Retrospective [2] 7.3 years (mean) 36 patients with RD 80.6% (patient based) 25% (patient based) RDs are associated neither with higher risk of implant failure nor peri-implant pathology (>4 mm pocket depth with BoP or MBL). However, it is associated with a higher number of implant failures

Table 11.

Studies that indicate dental implant outcomes in patients with rheumatologic disorders.

RD, rheumatologic disease; RA, rheumatoid arthritis; BoP, bleeding on probing; MBL, marginal bone loss; DI, dental implant; SR, survival rate; ND, no data available; OR, odds ratio.

2.11. Bisphosphonate therapy

Bisphosphonates (BFs) suppress the osteoclast function and therefore are used for the treatment of disorders causing abnormal bone resorption such as OP, malignancies (multiple myeloma, bone metastases of breast, or prostate cancer), or nonmalignant bone diseases (the most prevalent of osteoporosis and Paget disease) [30, 37].

According to the recent meta-analyses, the consumption of oral BF in patients with OP could only be assumed to be a relative contraindication for DI. Further, there is no evidence that any BFs have a negative impact upon implant survival. In this context, patients should be informed about the related risks and DI could be placed under optimum oral care conditions. On the contrary, in patients who are under BF treatment intravenously together with RT doses of above 50 Gy, DI placement was reported to be a contraindication [30, 56].

In conclusion, BFs do not seem to have an adverse effect on DI survival under optimum oral care conditions, and OBFs are not associated with occurrence of osteonecrosis of jaws (ONJ) ( Table 12 ).

Author, year, study design Follow-up No. of patients No. of implants SR of implant Peri-implant pathology Conclusion
Jeffcoat, 2006, Longitudinal single-blind controlled [57] 3 years 50 (the half is under OBF, the other half is not used BF) 210 100% for OBF, and 99.2% for control group OBF usage is not associated with occurrence of ONJ compared to placebo
Martin et al., 2010, Cohort [58] >1 year 589 aged women ND 26 implants loss in 16 patients Implant failure occurred as early as 4 weeks and as late as 11 years after placement
Famili et al., 2011, Retrospective [59] 1 year 211 women 347 98.7% OBF therapy is not significantly affects implant success
Al-Sabbagh et al., 2015, Retrospective [60] 6 years 39 51 86.4% It is suggested that there is a possible association between implant failure and not using of BF in elder patients (OR: 9.22)
Mozzati et al., 2015, Clinical chart review [61] 10 years 235 middle-aged women under OBPs for OP 1267 98.7% (implant based) 93.2% (patient based) The risk for developing BRONJ associated to DI surgery remains low for patients receiving oral BPs. The use of procedures that could enhance healing such as platelet concentrates is recommended
Siebert et al., 2015, Comparative prospective [54] 1 year 24 women (half under iv. BF, others without OP) 120 100% ND (MBL is similar) Immediate implant osseointegration can be successful in a patient with OP using once-yearly infusion of 5 mg iv. zoledronic acid
Suvarna et al., 2016, Retrospective [62] 3 years 112 (58 patients on OBF therapy) 140 92% No significant risk of implant failure is seen in patients on OBP therapy compared with healthy patients
Tallarico et al., 2016, Prospective [63] 3 years 32 98 98% 1.35 ± 0.21 No prosthesis failed during the entire follow-up, and no major complications were recorded. OBF therapy is not significantly affecting DI success in case of accurate treatment selection, minimally invasive surgical approach and constant follow-up
Ata-Ali et al., 2016, Systematic review and meta-analysis [56] 1–7 years 1288 patients (386 cases and 902 controls) 4562 (1090 DI in cases, 3472 in controls) Ranged between 66.7 and 100% in BF users, 95.5 and 100% in nonusers There is not enough evidence that BFs have a negative impact upon implant SR
Further, prospective studies involving larger sample sizes and longer durations of follow-up are required to confirm these results
Mean/total of values/subjects 1–10 years 1238 2233 (in 7 out of 8 available studies) SR is about 97% in patients who are under BFs therapy 1.35 mm at 3rd year follow-up (in one study available) BFs do not seem to have an adverse effect on DI survival under an optimum oral care conditions, and OBFs are not associated with occurrence of ONJ

Table 12.

Studies that indicate dental implant outcomes in patients who underwent bisphosphonate treatment.

BF, bisphosphonate; OBF, oral bisphosphonate; OP, osteoporosis; BRONJ, BP-related osteonecrosis of the jaws; ONJ, osteonecrosis of the jaws; MBL, marginal bone loss; DI, dental implant; SR, survival rate; ND, no data available.

Author, year, study design Follow-up No. of patients No. of implants SR of implant Peri-implant pathology Conclusion
Kovacs, 2001, Retrospective [65] 10 years (3 years of mean) 30 (received postsurgical adjuvant CT) and 17 (received only oncological surgery) 106 in CT group,
54 in surgery group
98.1% on implant basis CT is not detrimental to the survival and success of DIs in the mandible
Cao and Weischer, 2003 [66] (abstract available) ? 27 total number of nonirradiated and irradiated patients 131 total 65% on patient basis Implants and prostheses in irradiated patients have significantly lower survival rates than in nonirradiated patients
Korfage et al., 2011, Prospective [67] 5 years 50 (18 patients were treated with surgery only, 32 patients with RT in addition to the surgery) 195 (72 in surgery-, and 123 in surgery + RT) 98.6% for non-RT treated, 89.4% for RT-treated group Implant loss is higher in patients with head and neck cancer who received RT posttumor surgery
Gander et al., 2014, Retrospective [26] 20 months 33 (29 patients with SCC, 24 underwent mandibular reconstruction) 136 total 92.5% (at 1st year), 87.5% (after 20th month) Only smoking (p = 0.016) and alcohol abuse (p = 0.001) are associated with higher implant failure rates

Table 13.

Studies that indicate dental implant outcomes in head and neck oncology patients.

SCC, squamous cell carcinoma; CT, chemotherapy; RT, radiotherapy; DI, dental implant; SR, survival rate; ND, no data available.

Author, year, study design Follow-up No. of patients No. of implants SR of implant Peri-implant pathology Conclusion
Moy et al., 2005, Retrospective cohort [6] 2–20 years 22 patients received RT ND 68.18% in irradiated patients There is a correlation between head and neck radiation and increased failure rate (RR = 2.73)
Alsaadi et al., 2008, Retrospective [21] 2 years 2 patients received RT 15 in irradiated patients 80% RT is affected significantly the late implant loss (OR: 3.32)
Carr, 2012, Retrospective case series [69] 2 years ND (412 total) ND (1512 total) ND ND Late implant failure is influenced by the local factor of “implant location” and the systemic factor of “radiotherapy”
Mancha, 2012, Retrospective [70] 5 years 30 RT-group, 20 control (non-RT treated oral cancer group) 225 in RT group, 130 in control group 92.6% for irradiated (48.3% for ORN-developed patients) Irradiated patients have significantly higher implant loss than nonirradiated patients (p = 0.063)
Korfage et al., 2014, Retrospective [71] 14 years 164 patients with oral cancer (also 91 of them are smoker, 65 are nonsmoker) 318 in RT-group, 206 in nonirradiated group 91.5% for irradiated, 99.5% for nonirradiated Implant loss is higher in irradiated patients (p < 0.001) but no significant difference is shown for bone loss assessed on panoramic radiographs Smoking is also not found associated with the occurrence of ORN
Rana et al., 2016, Retrospective [72] 5 years 46 patients with oral cancer 162 67% (52 implant had lost) RT dose of <50 Gy units also showed significantly increased amount of implant survival rate
Nooh, 2013, Systematic Review [68] 1–14 years 944 patients with oral cancer 3775 88.9% (for 3357 implants) In preimplantation RT, SR of DI is significantly higher for the mandible (93.3%) than for the maxilla (78.9%) or for grafted bone (87.5%) While RT dose above 55 Gy significantly decreased implant survival
Mean/total of values/subjects 1–20 years 284 patients with oral cancer (in 5 out of 6 available studies), 54 irradiated patients (in 3/6) 720 implants in irradiated patients (in 4 out of 6 available studies) Approx. 83.07% SR in irradiated patients RT, especially a dose above 50 Gy, negatively affects DI success

Table 14.

Studies that indicate dental implant outcomes in patients who underwent radiation therapy.

ORN, osteoradionecrosis; RT, radiotherapy; DI, dental implant; OR, odds ratio; RR, risk ratio; SR, survival rate; ND, no data available.

2.12. Head and neck cancer

Squamous cell carcinoma, adenocarcinoma, and ameloblastoma are the most common malignancies that are encountered in the head and neck regions. These patients with malignancies frequently go under challenging adjuvant therapeutic procedures such as radiotherapy (RT) or chemotherapy (CT) in addition to the tumor surgery. Due to the aggressive nature of the cancer and challenging cancer therapies, it is difficult to manage the DI surgery and prosthetic procedures.

Furthermore, studies that evaluate the DI success in cancer patients are limited because most of the studies had a control group of patients who are under another cancer treatment (instead of a healthy control group) or have no control subjects to compare the success of dental implants. Therefore, the results are sufficient to achieve a conclusion regarding DI success (Tables 13 and 14). According to these clinical studies, CT does not seem to be associated with the higher DI failure when compared with the surgical treatment only. RT seems to be impairing the osseointegration process. Regardless of the cancer-treatment procedure, smoking and alcohol consumption in patients diagnosed with head and neck cancer yield higher implant failures. Additionally, there are no studies about implant therapy in patients with malignant diseases that are treated with BFs [64], and no study determined peri-implant conditions of DI in such patient population.

For improving the DI success in cancer patients, implant surgery is recommended to be performed at least 21 days prior to the initiation or following after 9 months of radiotherapy under a strict surgical asepsis and antimicrobial prophylaxis. Premature loading of the implants should be avoided [28, 31].

2.12.1. Radiotherapy and hyperbaric oxygen therapy

RT reduces the cellular and vascular processes of healing, therefore it is assumed to impair the osseointegration and increase the risk of DI-related complications [31]. RT doses higher than 50 Gy are known to hinder osseointegration of DIs [30]. On the other hand, DI placement becomes contraindicated in patients who have received additional therapy of BFs intravenously or hormonal therapy, corticosteroids or immunosuppressive medication [30]. According to the data retrieved from the recent studies, it can be concluded that implant loss is clearly higher in irradiated patients (Table 14). The failures are more prominent in mandible or in grafted bone [68].

In the past, adjuvant hyperbaric oxygen therapy (HBO) treatment was shown to lead lower DI failure rates in cancer patients who underwent RT than those nonirradiated and irradiated patients [73]. Whereas, according to the recent clinical studies and reviews ( Table 15), it seems that HBO has no positive effect on implant survival in irradiated patients. Therefore, this issue remains controversial.

Author, year, study design Follow-up No. of patients No. of implants SR of implant Peri-implant pathology Conclusion
Schoen et al., 2007, RCT [74] 1 year 26 (the half is HBO treated, others is control) ND 85.2% in HBO group, 93.9% in non-HBO group MBLs: 0.6 ± 0.6 mm in HBO-, 0.7 ± 0.7 mm in non-HBO group Adjuvant hyperbaric oxygen therapy does not influence implant survival or peri-implant MBL in radiated mandibular jaw bone. There is no statistically significant difference for postoperative complications and patient satisfaction
Esposito and Worthington, 2013, Systematic review [75] Despite the limited amount of clinical research available, it appears that HBO therapy in irradiated patients requiring dental implants may not offer any appreciable clinical benefits. There is a definite need for more RCTs to ascertain the effectiveness of HBO in irradiated patients requiring dental implants
Chambrone et al., 2013, Systematic review [76] 1689 in irradiated jaws The mean SR of 15 studies ranged from 46.3 to 98.0% The risk of implant failure increases significantly in irradiated patients (RR: 2.74) and in maxillary sites (RR: 5.96). HBO therapy does not reduce the risk of implant failure

Table 15.

The effect of hyperbaric oxygen (HBO) on reducing the risk of DI failure in irradiated patients.

HBO, hyperbaric oxygen; RR, risk ratio; RCT, randomized controlled trial; MBL, marginal bone loss.

2.13. Immunosuppressive conditions

Immunosuppressive disabilities encompass several disorders and conditions including RDs, autoimmune skin diseases (scleroderma, pemphigus, burning mouth syndrome etc.), organ transplantation, and immunosuppressive drug usage [2, 77, 78].

Since a good immune response is necessary for wound healing, immunocompromised conditions have been commonly assumed as a contraindication for DI placement [31]. In animal studies, it is showed that immunosuppressive drugs reduce osteoblast’s proliferation and impair implant osseointegration [79, 80]. Furthermore, immunocompromised condition may present additional risks for blood borne infections [28]. Therefore, installation of DIs in patients under long-term immunosuppressive treatment should be elucidated with additional measures [81].

2.13.1. Organ transplantation

Bone healing is negatively affected by immunosuppressive medications. There are reports of case series and clinical studies that show successful treatments of DIs in patients who underwent organ transplants (Table 16). Reviewers stated that DIs could be a valid treatment providing that the appropriate surgical procedures and hygienic conditions are ensured [28, 78]. Modification of the immunosuppressive medication could lead a significantly lower toxicity [78].

Author, year, study design Follow-up No. of patients No. of implants SR of implant Peri-implant pathology Conclusion
Gu and Yu, 2011, Case series [82] 3 years 13 45 100% MBL is 1.30 mm DI treatment can be offered to liver transplant patients who are stable under long-term immunosuppression. Stable liver function and general condition should be affirmed though overall examination and consultation
Gu et al., 2011, Case report [83] (only abstract available) 5 years 1 11 A stable osseointegration with moderate vertical bone loss is achieved
Montebugnoli et al., 2012, Prospective [84] 3 months 20 (10 have organ transplant, the other 10 are in control group) 32 (20 in transplanted, 12 in control group) MBL is 0.21 mm for transplanted, 0.32 mm is for control group The bone response around submerged DI in immunocompromised organ transplant patients does not differ from that observed in control patients
Montebugnoli et al., 2015, Prospective [81] 1 year 13 organ transplanted (11 hearts, two livers, and 13 control subjects) 29 in transplanted,
28 in healthy control subjects
For transplanted and control subjects, MBLs are 0.17 and 0.20 mm, PDs are 0.06 and 0.11 mm It seems that bone and periodontal response and microbiological status around submerged DI in immunocompromised organ-transplanted patients do not differ 1 year after loading from those observed in healthy control patients
Mean/total of values/subjects 1–5 years 37 patients had organ-transplant 105 implants 100% 0.19 mm for 1st year
1.30 mm at 3rd year
SR outcome is scarce. MBL seems acceptable More studies needed

Table 16.

Studies that indicate dental implant outcomes in patients who received organ transplant.

MBL, marginal bone loss; DI, dental implant; SR, survival rate; PD, pocket depth.

As a conclusion, it is apparent that DI is not contraindicated for the patients who had organ transplants. However, it is suggested that the patients’ medical condition should be investigated with the relevant physician before DI surgery, and the surgery should also be conducted under prophylactic medication in order to reduce the risk of blood-borne infections [28, 31].

2.13.2. HIV-positive patients

Acquired immune deficiency syndrome (AIDS) is a condition that is caused by the infection of the human immunodeficiency virus (HIV). HIV-infected individuals may have compromised oral health because of having HIV-associated gingivitis and periodontitis etc. [85] that yield an additional impairment of the general health.

Recently, HIV-infection is regarded as a chronic disease rather than a terminal disease owing to the therapeutic regimen of highly active antiretroviral therapy (HAART) that includes combinations of diverse antiretroviral medications. This regimen, however, is associated with many adverse effects including bone disorders, osteopenia, osteonecrosis, and osteoporosis [86, 87]. Hence, there is a need for identifying the predictability of dental implant therapy in patients with HIV-infection.

According to the clinical studies available ( Table 17 ), clinical outcomes regarding the peri-implant pathology are conflicting. There may be a tendency for peri-implant infections due to the immunocompromised condition. However, HIV infection does not seem to increase the failure in the short or long term. So DI could be regarded as an eligible treatment for improving quality of life in the HIV-positive patients.

Author, year, study design Follow-up No. of patients No. of implants SR of implant Peri-implant pathology Conclusion
Stevenson et al., 2007, Prospective [88] 6 months 20 HIV+, and 9 HIV− edentulous adults 40 in HIV+, 18 in HIV− subjects 100% for both groups No difference in short-term clinical outcome is found between the HIV+ and the HIV− subjects
Oliveira et al., 2011, Pilot study [89] 1 year 40 (11 PI-based HAART, 14 NNRTI-based HAART without PI, 15 control group of who had HIV−) 60 (20 in each groups) 100% for all groups 0.49 mm in PI-HAART group, 0.47 mm in NNRTI-HAART and 0.55 mm in control The placement of DI in HIV+ patients is a reasonable treatment, regardless of CD4+ cell count, viral load levels, and type of antiretroviral therapy. Longer follow-ups are necessary to ascertain the success
Neves et al., 2016, Retrospective [2] 7.3 years of mean 5 HIV+ ND 60% (patient based) 60% (patient-based peri-implant pathology rate) AIDS is not risk factor for neither higher implant failure nor peri-implant pathology (>4 mm pocket depth with BoP or MBL). However, these rates are high when compared mean failure rates of population
Gherlone et al., 2016, Prospective [90, 91] 1 year 66 HIV+ 190 92.1% on implant basis (a, b) MBL is 1.19 mm, peri-implantitis prevalence is 5.2% on implant basis (a, b) Despite higher incidence of peri-implant infections in the first 6 months (a), DI is a suitable treatment with a slightly worse results (a, b) regardless of CD4+ cell count (b). HIV+ heavy smokers (>10 cig/day) demonstrated increased risk of early failure, peri-implantitis, pus, and pain (b)
Gay-Escoda et al., 2016, Retrospective case series [92] 6.5 years of mean 9 HIV+ 57 98.3% Success rate: 68.4%. Patient- and implant-based rates of peri-implant mucositis: 22.2%–10.5%, peri-implantitis: 44.4%–45.6% Though there is a high prevalence of peri-implant diseases, DI in HIV+ patients seem to provide satisfactory clinical results
Mean/total of values/subjects Up to 7.3 years 125 HIV+ patients 347 (in 4 out of 5 studies) Approx. 90% SR 0.83 mm MBL in 1st year. 50% of peri-implant pathology rate for mean follow-up of 7 years SR is acceptable. Mean MBL outcomes are scarce and conflicting. Peri-implant pathology incidences seem higher as compared to the healthy population

Table 17.

Studies that indicate dental implant outcomes in HIV-infected patients.

HAART, highly active anti-retroviral therapy; PI, protease inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; MBL, marginal bone loss; BoP, bleeding on probing; SR, survival rate; resp, respectively.

2.14. Psychiatric disorders

Patients with neurologic disorders or other disabilities such as cerebral palsy, mental retardation, epilepsy, Down syndrome, Rett’s syndrome, Asperger syndrome, Prader-Willi syndrome, fragile X chromosome, dystrophia myotonica, autism, and schizophrenia cause many problems during implant treatment and prosthetic maintenance [93]. Epilepsy impairs the oral condition of patients due to nausea-induced vomiting, mechanical trauma caused by seizures, and antiepileptic drugs-associated oral complications such as gingival overgrowth, xerostomia, and yeast infections [94, 95]. Likewise, most widely used antidepressant drugs, selective serotonin reuptake inhibitors (SSRIs), affect not only the nervous system but also peripheral tissues including bones because of having serotonin receptors [96]. Therefore, SSRI blocks on bone cells have been reported to affect bone formation negatively [97].

Since bone metabolism and oral conditions have an influence on the osseointegration of DI, neuropsychiatric disabilities and the drugs used are considerable issues for DI treatment. Clinical research related to the effect of psychiatric disorders on DI success is limited. It seems that this kind of disorders do not cause higher failures or peri-implant pathology ( Table 18 ). On the other hand, SSRIs might increase DI failure rate as presented in a cohort study with a large number of subjects. Further studies are required to ascertain the association between antidepressant drugs and DI failure.

Author, year, study design Follow-up No. of patients No. of implants SR of implant Peri-implant pathology Conclusion
Cune et al., 2009, Retrospective [95] 16 years 61 patients with epilepsy, additional motor and/or intellectual impairments 134 97.6% 72% of implants were considered having inadequate level of hygiene PD is 2 mm Although adequate plaque control is not feasible in those patients, MBLs remained stable and implant loss is rare
Ekfeldt et al., 2013, Prospective [93] 10 years 22 patients with different neurologic disabilities 70 85.8% Peri-mucositis: 14 implants in 10 patients (PD ≥ 4 mm). Peri-implantitis: 4 implants in 3 patients (bone loss ≥ 3 threads) DI is a valid option in patients with ND, although maintenance often requires the management of more complications compared with healthy patients
Wu et al., 2014, Retrospective cohort [98] 3–67 months 490 total number of SSRI-users and nonusers 916 (94 in users, 822 in nonusers) 88.4% for users, 95.4% for nonusers SSRI is associated with increased failure risk of osseointegrated implants, which might suggest a careful surgical treatment planning for SSRI users

Table 18.

Studies that indicate dental implant outcomes in patients with psychiatric disorders.

ND, neurologic disabilities; SSRI, selective serotonin reuptake inhibitor; PD, probing depth; MBL, marginal bone loss; SR, survival rate.

Advertisement

3. Conclusion

Implant survival in the elderly population, osteoporosis (OP) and HIV infection seem to be similar with the healthy population. CVDs or diabetes may present a small risk. RT seems to have the worst effect on DI success with an average SR of 83%. Some of the other compromised conditions such as alcoholism, bleeding disorders, thyroid disorders, hepatitis, RDs, organ transplantation, and HBO therapy should be investigated with additional clinical data to reveal objective conclusions regarding DIs.

Results with regard to peri-implantitis or peri-implant conditions are insufficient and even conflicting for majority of the compromising systemic aspects. Future studies should be designed for indicating peri-implant tissue health and maintenance in compromised patients.

It must be taken into account that follow-up of the patients in a professional oral maintenance regimen after implant placement reduces the implant failure rate by 80% [12]. Thus, it can be stated that controlling the systemic diseases before the implant therapy and proper establishment of the medical conditions are more important than the presence of a compromise alone.

Advertisement

Acknowledgments

This study was supported by Istanbul University Research Fund.

References

  1. 1. Austin S, Bailey D, Chandu A, Dastaran M, Judge R. Analysis of commonly reported medical conditions amongst patients receiving dental implant therapy in private practice. Australian Dental Journal. 2015;60(3):343-352. DOI: 10.1111/adj.12237
  2. 2. Neves J, de Araújo Nobre M, Oliveira P, Martins Dos Santos J, Malo P. Risk Factors for Implant Failure and Peri-Implant Pathology in Systemic Compromised Patients. J Prosthodont. 2016 Jun 27. DOI: 10.1111/jopr.12508. [Epub ahead of print]
  3. 3. Bartold PM, Ivanovski S, Darby I. Implants for the aged patient: Biological, clinical and sociological considerations. Periodontology 2000. 2016;72(1):120-134. DOI: 10.1111/prd.12133
  4. 4. Srinivasan M, Meyer S, Mombelli A, M?ller F. Dental implants in the elderly population: a systematic review and meta-analysis. Clin Oral Implants Res. 2017;28(8):920-930. DOI: 10.1111/clr.12898
  5. 5. Hoeksema AR, Visser A, Raghoebar GM, Vissink A, Meijer HJ. Influence of age on clinical performance of mandibular two-implant overdentures: A 10-year prospective comparative study. Clinical Implant Dentistry and Related Research. 2016;18(4):745-751. DOI: 10.1111/cid.12351
  6. 6. Moy PK, Medina D, Shetty V, Aghaloo TL. Dental implant failure rates and associated risk factors. The International Journal of Oral & Maxillofacial Implants. 2005;20(4):569-577
  7. 7. Manor Y, Oubaid S, Mardinger O, Chaushu G, Nissan J. Characteristics of early versus late implant failure: A retrospective study. Journal of Oral and Maxillofacial Surgery. 2009;67(12):2649-2652. DOI: 10.1016/j.joms.2009.07.050
  8. 8. Lee HJ, Kim YK, Park JY, Kim SG, Kim MJ, Yun PY. Short-term clinical retrospective study of implants in geriatric patients older than 70 years. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics. 2010;110(4):442-446. DOI: 10.1016/j.tripleo.2010.02.019
  9. 9. Busenlechner D, Fürhauser R, Haas R, Watzek G, Mailath G, Pommer B. Long-term implant success at the Academy for Oral Implantology: 8-year follow-up and risk factor analysis. Journal of Periodontal & Implant Science. 2014;44(3):102-108. DOI: 10.5051/jpis.2014.44.3.102
  10. 10. Becker W, Hujoel P, Becker BE, Wohrle P. Dental implants in an aged population: Evaluation of periodontal health, bone loss, implant survival, and quality of life. Clinical Implant Dentistry and Related Research. June 2016;18(3):473-479. DOI: 10.1111/cid.12340
  11. 11. Prasad S, Hambrook C, Reigle E, Sherman K, Bansal N, Hefti A. Implant Treatment in the Predoctoral Clinic: A Retrospective Database Study of 1091 Patients. J Prosthodont. 2016 Nov 22. DOI: 10.1111/jopr.12570
  12. 12. Tran DT, Gay IC, Diaz-Rodriguez J, Parthasarathy K, Weltman R, Friedman L. Survival of dental implants placed in grafted and nongrafted bone: A retrospective study in a university setting. The International Journal of Oral & Maxillofacial Implants. 2016;31(2):310-317. DOI: 10.11607/jomi.4681
  13. 13. Niedermaier R, Stelzle F, Riemann M, Bolz W, Schuh P, Wachtel H. Implant-supported immediately loaded fixed full-arch dentures: Evaluation of implant survival rates in a case cohort of up to 7 years. Clinical Implant Dentistry and Related Research. 2017;19(1):4-19. DOI: 10.1111/cid.12421
  14. 14. Clementini M, Rossetti PH, Penarrocha D, Micarelli C, Bonachela WC, Canullo L. Systemic risk factors for peri-implant bone loss: A systematic review and meta-analysis. International Journal of Oral and Maxillofacial Surgery. 2014;43(3):323-334. DOI: 10.1016/j.ijom.2013.11.012
  15. 15. Galindo-Moreno P, Fauri M, Avila-Ortiz G, Fernández-Barbero JE, Cabrera-León A, Sánchez-Fernández E. Influence of alcohol and tobacco habits on peri-implant marginal bone loss: A prospective study. Clinical Oral Implants Research. 2005;16(5):579-586. DOI: 10.1111/j.1600-0501.2005.01148.x
  16. 16. Krennmair S, Weinländer M, Forstner T, Krennmair G, Stimmelmayr M. Factors affecting peri-implant bone resorption in four Implant supported mandibular full-arch restorations: A 3-year prospective study. Journal of Clinical Periodontology. 2016;43(1):92-101. DOI: 10.1111/jcpe.12469
  17. 17. Ekfeldt A, Christiansson U, Eriksson T, Lindén U, Lundqvist S, Rundcrantz T, Johansson LA, Nilner K, Billström C. A retrospective analysis of factors associated with multiple implant failures in maxillae. Clinical Oral Implants Research. 2001;12(5):462-467
  18. 18. Alsaadi G, Quirynen M, Komárek A, van Steenberghe D. Impact of local and systemic factors on the incidence of oral implant failures, up to abutment connection. Journal of Clinical Periodontology. 2007;34(7):610-617. DOI: 10.1111/j.1600-051X.2007.01077.x
  19. 19. Holahan CM, Koka S, Kennel KA, Weaver AL, Assad DA, Regennitter FJ, Kademani D. Effect of osteoporotic status on the survival of titanium dental implants. The International Journal of Oral & Maxillofacial Implants. 2008;23(5):905-910
  20. 20. Sverzut AT, Stabile GA, de Moraes M, Mazzonetto R, Moreira RW. The influence of tobacco on early dental implant failure. Journal of Oral and Maxillofacial Surgery. 2008;66(5):1004-1009. DOI: 10.1016/j.joms.2008.01.032
  21. 21. Alsaadi G, Quirynen M, Komárek A, van Steenberghe D. Impact of local and systemic factors on the incidence of late oral implant loss. Clinical Oral Implants Research. 2008;19:670-676. DOI: 10.1111/j.1600-0501.2008.01534.x
  22. 22. Alsaadi G, Quirynen M, Michiles K, Teughels W, Komárek A, van Steenberghe D. Impact of local and systemic factors on the incidence of failures up to abutment connection with modified surface oral implants. Journal of Clinical Periodontology. 2008;35(1):51-57. DOI: 10.1111/j.1600-051X.2007.01165.x
  23. 23. Lee JY, Park HJ, Kim JE, Choi YG, Kim YS, Huh JB, Shin SW. A 5-year retrospective clinical study of the Dentium implants. The Journal of Advanced Prosthodontics. December 2011;3(4):229-235. DOI: 10.4047/jap.2011.3.4.229
  24. 24. Cakarer S, Selvi F, Can T, Kirli I, Palancioglu A, Keskin B, Yaltirik M, Keskin C. Investigation of the risk factors associated with the survival rate of dental implants. Journal of Implant Dentistry. 2014;23(3):328-333. DOI: 10.1097/ID.0000000000000079
  25. 25. Pedro RE, De Carli JP, Linden MS, Lima IF, Paranhos LR, Costa MD, Bós ÂJ. Influence of age on factors associated with peri-implant bone loss after prosthetic rehabilitation over osseointegrated implants. The Journal of Contemporary Dental Practice. 2017;18(1):3-10
  26. 26. Gander T, Studer S, Studer G, Grätz KW, Bredell M. Medium-term outcome of Astra Tech implants in head and neck oncology patients. International Journal of Oral and Maxillofacial Surgery. 2014;43(11):1381-1385. DOI: 10.1016/j.ijom.2014.05.005
  27. 27. Scully C, Hobkirk J, Dios PD. Dental endosseous implants in the medically compromised patient. Journal of Oral Rehabilitation. 2007;34(8):590-599. DOI: 10.1111/j.1365-2842.2007.01755.x
  28. 28. Diz P, Scully C, Sanz M. Dental implants in the medically compromised patient. Journal of Dentistry. 2013;41(3):195-206. DOI: 10.1016/j.jdent.2012.12.008
  29. 29. Elsubeihi ES, Zarb GA. Implant prosthodontics in medically challenged patients: The University of Toronto experience. Journal of the Canadian Dental Association. 2002;68(2):103-108
  30. 30. Gómez-de Diego R, Mang-de la Rosa Mdel R, Romero-Pérez MJ, Cutando-Soriano A, López-Valverde-Centeno A. Indications and contraindications of dental implants in medically compromised patients: Update. Medicina Oral, Patología Oral y Cirugía Bucal Journal. 2014;19(5):e483-e489
  31. 31. Donos N, Calciolari E. Dental implants in patients affected by systemic diseases. British Dental Journal. 2014;217(8):425-430. DOI: 10.1038/sj.bdj.2014.911
  32. 32. Farbod F, Kanaan H, Farbod J. Infective endocarditis and antibiotic prophylaxis prior to dental/oral procedures: Latest revision to the guidelines by the American Heart Association published April 2007. International Journal of Oral and Maxillofacial Surgery. 2009;38(6):626-631. DOI: 10.1016/j.ijom.2009.03.717
  33. 33. Esposito M, Worthington HV, Loli V, Coulthard P, Grusovin MG. Interventions for replacing missing teeth: Antibiotics at dental implant placement to prevent complications. Cochrane Database of Systematic Reviews. 2010;(7):CD004152. DOI: 10.1002/14651858.CD004152.pub3. https://www.ncbi.nlm.nih.gov/pubmed/20614437
  34. 34. Findler M, Chackartchi T, Regev E. Dental implants in patients at high risk for infective endocarditis: A preliminary study. International Journal of Oral and Maxillofacial Surgery. 2014;43(10):1282-1285. DOI: 10.1016/j.ijom.2014.04.015
  35. 35. Hwang D, Wang HL. Medical contraindications to implant therapy: Part I: Absolute contraindications. Implant Dentistry. 2006;15(4):353-360. DOI: 10.1097/01.id.0000247855.75691.03
  36. 36. Hwang D, Wang HL. Medical contraindications to implant therapy: Part II: Relative contraindications. Implant Dentistry. 2007;16(1):13-23. DOI: 10.1097/ID.0b013e31803276c8
  37. 37. Bornstein MM, Cionca N, Mombelli A. Systemic conditions and treatments as risks for implant therapy. The International Journal of Oral & Maxillofacial Implants. 2009;24(Suppl):12-27
  38. 38. Nobre Mde A, Maló P, Gonçalves Y, Sabas A, Salvado F. Outcome of dental implants in diabetic patients with and without cardiovascular disease: A 5-year post-loading retrospective study. European Journal of Oral Implantology. 2016;9(1):87-95
  39. 39. Michaeli E, Weinberg I, Nahlieli O. Dental implants in the diabetic patient: Systemic and rehabilitative considerations. Quintessence International. 2009;40(8):639-645
  40. 40. Oates TW, Huynh-Ba G, Vargas A, Alexander P, Feine J. A critical review of diabetes, glycemic control, and dental implant therapy. Clinical Oral Implants Research. 2013;24(2):117-127. DOI: 10.1111/j.1600-0501.2011.02374.x
  41. 41. Shi Q, Xu J, Huo N, Cai C, Liu H. Does a higher glycemic level lead to a higher rate of dental implant failure?: A meta-analysis. Journal of the American Dental Association. 2016;147(11):875-881. DOI: 10.1016/j.adaj.2016.06.011
  42. 42. Napeñas JJ, Hong CH, Brennan MT, Furney SL, Fox PC, Lockhart PB. The frequency of bleeding complications after invasive dental treatment in patients receiving single and dual antiplatelet therapy. Journal of the American Dental Association. 2009;140(6):690-695
  43. 43. Madrid C, Sanz M. What impact do systemically administrated bisphosphonates have on oral implant therapy? A systematic review. Clinical Oral Implants Research. 2009;20(Suppl 4):87-95. DOI: 10.1111/j.1600-0501.2009.01772.x
  44. 44. Bacci C, Berengo M, Favero L, Zanon E. Safety of dental implant surgery in patients undergoing anticoagulation therapy: A prospective case-control study. Clinical Oral Implants Research. 2011;22(2):151-156. DOI: 10.1111/j.1600-0501.2010.01963.x
  45. 45. Clemm R, Neukam FW, Rusche B, Bauersachs A, Musazada S, Schmitt CM. Management of anticoagulated patients in implant therapy: A clinical comparative study. Clin Oral Implants Res. 2016;27(10):1274-1282. DOI: 10.1111/clr.12732
  46. 46. Marković A, Đinić A, Calvo Guirado JL, Tahmaseb A, Šćepanović M, Janjić B. Randomized clinical study of the peri-implant healing to hydrophilic and hydrophobic implant surfaces in patients receiving anticoagulants. Clin Oral Implants Res. 2016 Aug 18. DOI: 10.1111/clr.12948
  47. 47. Feitosa Dda S, Bezerra Bde B, Ambrosano GM, Nociti FH, Casati MZ, Sallum EA, de Toledo S. Thyroid hormones may influence cortical bone healing around titanium implants: A histometric study in rats. Journal of Periodontology. 2008;79(5):881-887. DOI: 10.1902/jop.2008.070466
  48. 48. Smirnova OA, Ivanov AV, Ivanova ON, Valuev-Éllison VT, Kochetkov SN. Cellular defense systems against oxidative and ER stresses: Mechanisms of regulation and influence of hepatitis C virus. Molecular Biology (Mosk). 2011;45(1):127-141
  49. 49. Coates EA, Brennan D, Logan RM, Goss AN, Scopacasa B, Spencer AJ, Gorkic E. Hepatitis C infection and associated oral health problems. Australian Dental Journal. 2000;45:108-114
  50. 50. Marrone A, Lasserre J, Bercy P, Brecx MC. Prevalence and risk factors for peri-implant disease in Belgian adults. Clinical Oral Implants Research. 2013;24(8):934-940. DOI: 10.1111/j.1600-0501.2012.02476.x
  51. 51. Dvorak G, Arnhart C, Heuberer S, Huber CD, Watzek G, Gruber R. Peri-implantitis and late implant failures in postmenopausal women: A cross-sectional study. Journal of Clinical Periodontology. 2011;38(10):950-955. DOI: 10.1111/j.1600-051X.2011.01772.x
  52. 52. Temmerman A, Rasmusson L, Kübler A, Thor A, Quirynen M. An open, prospective, non-randomized, controlled, multicentre study to evaluate the clinical outcome of implant treatment in women over 60 years of age with osteoporosis/osteopenia: 1-year results. Clinical Oral Implants Research. 2017;28(1):95-102. DOI: 10.1111/clr.12766
  53. 53. Chow L, Chow TW, Chai J, Mattheos N. Bone stability around implants in elderly patients with reduced bone mineral density - a prospective study on mandibular overdentures. Clin Oral Implants Res. 2017;28(8):966-973. DOI: 10.1111/clr.12907
  54. 54. Siebert T, Jurkovic R, Statelova D, Strecha J. Immediate implant placement in a patient with osteoporosis undergoing bisphosphonate therapy: 1-year preliminary prospective study. Journal of Oral Implantology. 2015;41(1):360-365. DOI: 10.1563/AAID-JOI-D-13-00063
  55. 55. Krennmair G, Seemann R, Piehslinger E. Dental implants in patients with rheumatoid arthritis: Clinical outcome and peri-implant findings. Journal of Clinical Periodontology. 2010;37(10):928-936. DOI: 10.1111/j.1600-051X.2010.01606.x
  56. 56. Ata-Ali J, Ata-Ali F, Peñarrocha-Oltra D, Galindo-Moreno P. What is the impact of bisphosphonate therapy upon dental implant survival? A systematic review and meta-analysis. Clinical Oral Implants Research. 2016;27(2):e38-e46. DOI: 10.1111/clr.12526
  57. 57. Jeffcoat MK. Safety of oral bisphosphonates: Controlled studies on alveolar bone. The International Journal of Oral & Maxillofacial Implants. 2006;21(3):349-353
  58. 58. Martin DC, O’Ryan FS, Indresano AT, Bogdanos P, Wang B, Hui RL, Lo JC. Characteristics of implant failures in patients with a history of oral bisphosphonate therapy. Journal of Oral and Maxillofacial Surgery. 2010;68(3):508-514. DOI: 10.1016/j.joms.2009.09.055
  59. 59. Famili P, Quigley S, Mosher T. Survival of dental implants among post-menopausal female dental school patients takingoral bisphosphonates: A retrospective study. Compendium of Continuing Education in Dentistry. 2011;32(6):E106-E109
  60. 60. Al-Sabbagh M, Thomas MV, Bhavsar I, De Leeuw R. Effect of bisphosphonate and age on implant failure as determined by patient-reported outcomes. Journal of Oral Implantology. 2015;41(6):e287-e291. DOI: 10.1563/aaid-joi-D-14-00195
  61. 61. Mozzati M, Arata V, Giacomello M, Del Fabbro M, Gallesio G, Mortellaro C, Bergamasco L. Failure risk estimates after dental implants placement associated with plasma rich in growth factor-Endoret in osteoporotic women under bisphosphonate therapy. Journal of Craniofacial Surgery. May 2015;26(3):749-755. DOI: 10.1097/SCS.0000000000001535
  62. 62. Suvarna S, Dutt P, Misra A, Usmani N, Singh A, Suvarna C. Intricate assessment and evaluation of dental implants in patients on bisphosphonate therapy: A retrospective analysis. The Journal of Contemporary Dental Practice. May 1 2016;17(5):414-417
  63. 63. Tallarico M, Canullo L, Xhanari E, Meloni SM. Dental implants treatment outcomes in patient under active therapy with alendronate: 3-year follow-up results of a multicenter prospective observational study. Clinical Oral Implants Research. August 2016;27(8):943-949. DOI: 10.1111/clr.12662
  64. 64. Walter C, Al-Nawas B, Wolff T, Schiegnitz E, Grötz KA. Dental implants in patients treated with antiresorptive medication—A systematic literature review. International Journal of Implant Dentistry. 2016;2(1):9. DOI: 10.1186/s40729-016-0041-7
  65. 65. Kovács AF. Influence of chemotherapy on endosteal implant survival and success in oral cancer patients. International Journal of Oral and Maxillofacial Surgery. 2001;30(2):144-147
  66. 66. Cao Y, Weischer T. Comparison of maxillary implant-supported prosthesis in irradiated and non-irradiated patients. Journal of Huazhong University of Science and Technology. Medical Sciences. 2003;23(2):209-212
  67. 67. Korfage A, Schoen PJ, Raghoebar GM, Bouma J, Burlage FR, Roodenburg JL, Vissink A, Reintsema H. Five-year follow-up of oral functioning and quality of life in patients with oral cancer with implant-retained mandibular overdentures. Head Neck. 2011;33(6):831-839. DOI: 10.1002/hed.21544
  68. 68. Nooh N. Dental implant survival in irradiated oral cancer patients: A systematic review of the literature. The International Journal of Oral & Maxillofacial Implants. 2013;28(5):1233-1242. DOI: 10.11607/jomi.3045
  69. 69. Carr AB. Implant location and radiotherapy are the only factors linked to 2-year implant failure. Journal of Evidence-Based Dental Practice. 2012;12(3 Suppl):217-219. DOI: 10.1016/S1532-3382(12)70042-8
  70. 70. Mancha de la Plata M, Gías LN, Díez PM, Muñoz-Guerra M, González-García R, Lee GY, Castrejón-Castrejón S, Rodríguez-Campo FJ. Osseointegrated implant rehabilitation of irradiated oral cancer patients. Journal of Oral and Maxillofacial Surgery. 2012;70(5):1052-1063. DOI: 10.1016/j.joms.2011.03.032
  71. 71. Korfage A, Raghoebar GM, Slater JJ, Roodenburg JL, Witjes MJ, Vissink A, Reintsema H. Overdentures on primary mandibular implants in patients with oral cancer: A follow-up study over 14 years. British Journal of Oral and Maxillofacial Surgery. 2014;52(9):798-805. DOI: 10.1016/j.bjoms.2014.05.013
  72. 72. Rana MC, Solanki S, Pujari SC, Shaw E, Sharma S, Anand A, Singh HP. Assessment of the survival of dental implants in irradiated jaws following treatment of oral cancer: A retrospective study. Nigerian Journal of Surgery. 2016;22(2):81-85
  73. 73. Granström G, Tjellström A, Brånemark PI. Osseointegrated implants in irradiated bone: A case-controlled study using adjunctive hyperbaric oxygen therapy. Journal of Oral and Maxillofacial Surgery. 1999;57(5):493-499
  74. 74. Schoen PJ, Raghoebar GM, Bouma J, Reintsema H, Vissink A, Sterk W, Roodenburg JL. Rehabilitation of oral function in head and neck cancer patients after radiotherapy with implant-retained dentures: Effects of hyperbaric oxygen therapy. Oral Oncology. 2007;43(4):379-388
  75. 75. Esposito M, Worthington HV. Interventions for replacing missing teeth: Hyperbaric oxygen therapy for irradiated patients who require dental implants. The Cochrane Database of Systematic Reviews. 2013;(9):CD003603. DOI: 10.1002/14651858.CD003603.pub3. https://www.ncbi.nlm.nih.gov/pubmed/24085641
  76. 76. Chambrone L, Mandia Jr J, Shibli JA, Romito GA, Abrahao M. Dental implants installed in irradiated jaws: A systematic review. Journal of Dental Research. 2013;92(12 Suppl):119S-130S. DOI: 10.1177/0022034513504947
  77. 77. Zigdon H, Gutmacher Z, Teich S, Levin L. Full-mouth rehabilitation using dental implants in a patient with scleroderma. Quintessence International. 2011;42(9):781-785
  78. 78. Radzewski R, Osmola K. The use of dental implants in organ transplant patients undergoing immunosuppressive therapy: An overview of publications. Implant Dentistry. 2016;25(4):541-546. DOI: 10.1097/ID.0000000000000417
  79. 79. Zheng X, Mo A, Wang Y, Guo Y, Wu Y, Yuan Q. Effect of FK-506 (tacrolimus) therapy on bone healing of titanium implants: A histometric and biomechanical study in mice. European Journal of Oral Sciences. 2017;125(1):28-33. DOI: 10.1111/eos.12320
  80. 80. Annussek T, Kleinheinz J, Thomas S, Joos U, Wermker K. Short time administration of antirheumatic drugs—Methotrexate as a strong inhibitor of osteoblast’s proliferation in vitro. Head & Face Medicine. 2012;8:26. DOI: 10.1186/1746-160X-8-26
  81. 81. Montebugnoli L, Venturi M, Cervellati F, Servidio D, Vocale C, Pagan F, Landini MP, Magnani G, Sambri V. Peri-implant response and microflora in organ transplant patients 1 year after prosthetic loading: A prospective controlled study. Clinical Implant Dentistry and Related Research. 2015;17(5):972-982. DOI: 10.1111/cid.12207
  82. 82. Gu L, Yu YC. Clinical outcome of dental implants placed in liver transplant recipients after 3 years: A case series. Transplantation Proceedings. 2011;43(7):2678-2682. DOI: 10.1016/j.transproceed.2011.06.037
  83. 83. Gu L, Wang Q, Yu YC. Eleven dental implants placed in a liver transplantation patient: A case report and 5-year clinical evaluation. Chinese Medical Journal (England). 2011;124(3):472-475
  84. 84. Montebugnoli L, Venturi M, Cervellati F. Bone response to submerged implants in organ transplant patients: A prospective controlled study. The International Journal of Oral & Maxillofacial Implants. 2012;27(6):1494-1500
  85. 85. Ryder MI, Nittayananta W, Coogan M, Greenspan D, Greenspan JS. Periodontal disease in HIV/AIDS. Periodontology 2000. 2012;60(1):78-97. DOI: 10.1111/j.1600-0757.2012.00445.x
  86. 86. Annapoorna N, Rao GV, Reddy NS, Rambabu P, Rao KR. An increased risk of osteoporosis during acquired immunodeficiency syndrome. International Journal of Medical Sciences. 2004;1(3):152-164
  87. 87. Hofman P, Nelson AM. The pathology induced by highly active antiretroviral therapy against human immunodeficiency virus: An update. Current Medicinal Chemistry. 2006;13(26):3121-3132
  88. 88. Stevenson GC, Riano PC, Moretti AJ, Nichols CM, Engelmeier RL, Flaitz CM. Short-term success of osseointegrated dental implants in HIV-positive individuals: A prospective study. The Journal of Contemporary Dental Practice. 2007;8(1):1-10
  89. 89. Oliveira MA, Gallottini M, Pallos D, Maluf PS, Jablonka F, Ortega KL. The success of endosseous implants in human immunodeficiency virus-positive patients receiving antiretroviral therapy: A pilot study. Journal of the American Dental Association. 2011;142(9):1010-1016
  90. 90. Gherlone EF, Capparé P, Tecco S, Polizzi E, Pantaleo G, Gastaldi G, Grusovin MG. Implant prosthetic rehabilitation in controlled HIV-positive patients: A prospective longitudinal study with 1-year follow-up. Clinical Implant Dentistry and Related Research. 2016;18(4):725-734. DOI: 10.1111/cid.12353
  91. 91. Gherlone EF, Capparé P, Tecco S, Polizzi E, Pantaleo G, Gastaldi G, Grusovin MG. A prospective longitudinal study on implant prosthetic rehabilitation in controlled HIV-positive patients with 1-year follow-up: The role of CD4+ level, smoking habits, and oral hygiene. Clinical Implant Dentistry and Related Research. 2016;18(5):955-964. DOI: 10.1111/cid.12370
  92. 92. Gay-Escoda C, Pérez-Álvarez D, Camps-Font O, Figueiredo R. Long-term outcomes of oral rehabilitation with dental implants in HIV-positive patients: A retrospective case series. Medicina Oral, Patología Oral y Cirugía Bucal. 2016;21(3):e385-e391
  93. 93. Ekfeldt A, Zellmer M, Carlsson GE. Treatment with implant-supported fixed dental prostheses in patients with congenital and acquired neurologic disabilities: A prospective study. The International Journal of Prosthodontics. 2013;26(6):517-524. DOI: 10.11607/ijp.3511
  94. 94. Stoopler ET, Sollecito TP, Greenberg MS. Seizure disorders: Update of medical and dental considerations. General Dentistry. 2003;51(4):361-366; quiz 367
  95. 95. Cune MS, Strooker H, van der Reijden WA, de Putter C, Laine ML, Verhoeven JW. Dental implants in persons with severe epilepsy and multiple disabilities: A long-term retrospective study. The International Journal of Oral & Maxillofacial Implants. May-June 2009;24(3):534-540
  96. 96. Tsapakis EM, Gamie Z, Tran GT, Adshead S, Lampard A, Mantalaris A, Tsiridis E. The adverse skeletal effects of selective serotonin reuptake inhibitors. European Psychiatry. 2012;27(3):156-169. DOI: 10.1016/j.eurpsy.2010.10.006
  97. 97. Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schütz G, Glorieux FH, Chiang CY, Zajac JD, Insogna KL, Mann JJ, Hen R, Ducy P, Karsenty G. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell. 2008;135(5):825-837. DOI: 10.1016/j.cell.2008.09.059
  98. 98. Wu X, Al-Abedalla K, Rastikerdar E, Abi Nader S, Daniel NG, Nicolau B, Tamimi F. Selective serotonin reuptake inhibitors and the risk of osseointegrated implant failure: A cohort study. Journal of Dental Research. 2014;93(11):1054-1061. DOI: 10.1177/0022034514549378

Written By

Ayşe Sümeyye Akay and Volkan Arısan

Submitted: 21 November 2016 Reviewed: 21 June 2017 Published: 20 December 2017